Evidence map›Paper›PMID 36376934›Full record

ArticleCancer cell international2022

New strategy for antimetastatic treatment of lung cancer: a hypothesis based on circulating tumour cells.

Zujun Que, Jianhui Tian

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Zujun QueInstitute of Oncology, Shanghai Municipal Hospital of TCM, Shanghai University of Traditional Chinese Medicine (TCM), Shanghai, 200071, People's Republic of China.
Jianhui TianInstitute of Oncology, Shanghai Municipal Hospital of TCM, Shanghai University of Traditional Chinese Medicine (TCM), Shanghai, 200071, People's Republic of China. tjhhawk@shutcm.edu.cn.
Shanghai University · CNShanghai University of Traditional Chinese Medicine · CN

Funding

National Natural Science Foundation of China 81803777National Natural Science Foundation of China 81973517Shanghai Frontier Research Base of Disease and Syndrome Biology of Inflammatory Cancer Transformation 2021KJ03-12
6 · The paper itself

Abstract

Metastasis is the primary cause of death in lung cancer patients. However, until now, effective drugs and intervention strategies for treating lung cancer metastasis have been lacking. This hypothesis focuses on circulating tumour cells (CTCs) to develop a new antimetastatic therapeutic strategy for lung cancer. Here, we outline the role of CTCs in tumour metastasis and their functional effects during the treatment of lung cancer patients. Additionally, we hypothesized the possibility of CTCs as a novel biomarker and therapeutic target in preventing and treating metastasis in patients with early-stage lung cancer. We hope that the realization of this hypothesis will improve the overall survival of lung cancer.

Indexed as

AntimetastaticBiomarkerCirculating tumour cellsLung cancerTherapeutic strategy

Identifiers

PMID36376934
PMCPMC9664634
OpenAlexW4308986100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.